2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

Othman Al Musaimi; Danah Al Shaer; Fernando Albericio; Beatriz G de la Torre

doi:10.3390/ph14020145

2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

Pharmaceuticals (Basel). 2021 Feb 11;14(2):145. doi: 10.3390/ph14020145.

Authors

Othman Al Musaimi¹, Danah Al Shaer², Fernando Albericio^{1

3

4}, Beatriz G de la Torre²

Affiliations

¹ School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
² KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
³ Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
⁴ Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain.

Abstract

2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.

Keywords: 64Cu-DOTATATE; 68Ga-PSMA-11; FDA; belantamab mafodotin-blmf; drugs; lumasiran; oligonucleotides; peptides; setmelanotide; viltolarsen.

Publication types

Review

Grants and funding

sGR/Generalitat de Catalunya